Robert Ashley

Robert Ashley joined the Provisio team in January 2022 as VP, Regulatory, Quality and Clinical Strategy. Rob has over 40 years of experience in the drug and device development industry, having “C” level positions for much of that time, and has participated in two successful IPOs. Most recently he was Head of Regulatory for Epirium Bio Inc., developing drugs for the treatment of musculoskeletal and neurological disorders. Prior to that he was COO and CTO of Vital Therapies, Inc., where he had responsibility for worldwide manufacturing, regulatory affairs and clinical development for a combination biologic/device for the treatment of acute liver failure. He was CEO of AmpliMed Corporation, developing drugs for the treatment of cancer, and Senior VP at CollaGenex Pharmaceuticals, developing and commercializing drugs for the treatment of dermatological disorders (sold to Galderma, Inc.). Prior to that he worked at Bristol-Myers Squibb and Amersham International in various roles including sales, marketing, product planning, research and manufacturing. He obtained his Masters in Biochemistry from the University of Oxford.